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ABSTRACT    
         








Giant cell hepatitis with autoimmune hemolytic anemia (GCH-AHA) is a rare disease of 
early childhood of unknown pathogenesis1. It is characterized by the association of an acute and 
severe liver injury with a diffuse giant cell transformation of hepatocytes and a Coombs-positive 
hemolytic anemia1,2. Although autoimmune liver disease-related autoantibodies are usually 
absent2, an autoimmune mechanism explaining liver injury has been hypothesized, because of the 
constant association with an autoimmune disease, the possible association with other immune-
mediated disorders such as Evan’s syndrome, the response to immunosuppressive therapy and 
the constant disease relapse when therapy is withdrawn or tapered in the first years of treatment 
2,3. Moreover, GCH-AHA is a therapeutic challenge with high mortality despite aggressive 
immunosuppression2 and recurrence after liver transplant 4. High dose corticosteroids associated 
with azathioprine have been shown to represent the most efficacious first-line treatment for these 
patients, even though associated with devastating side effects (dwarfism, cataracts, arterial 
hypertension, vertebral collapse) due to the early beginning in life of high doses of steroids and 
the need of maintaining it for years1,2. For this reason, a wide number of immunosuppressive 
drugs including, calcineurin inhibitors, sirolimus, micophenolate mophetil and cyclophosphamide 
have been tried, as an adjunct to corticosteroids, for inducing and maintaining remission, however 
with partial success2,5,6. The incomplete response to these immunosuppressive drugs, that are 
usually effective in the treatment of juvenile autoimmune hepatitis, might be explained by a 
different immune-mediated mechanism of liver injury in GCH-AHA, as compared to “classical”, T 
cell mediated liver injury, observed in juvenile autoimmune hepatitis7. This hypothesis is 
supported by a recent study which, by demonstrating of a diffuse C5b-9 complex deposition in 
giant hepatocytes, suggests that liver cell injury may be autoantibody-driven and complement-
mediated, as in the case of the associated Coombs positive hemolytic anemia 8. This has potential 
therapeutic implications and prolonged remission have been recently reported using B cell 
depletion immunotherapy with chimeric anti-CD20 monoclonal antibody (rituximab) 2,9,10. 
Intravenous immune globulins (IVIg) have been empirically used in patients with GCH-AHA, mainly 
at replacement dose and in single administration, for treating the autoimmune hemolytic anemia 
before the onset of liver disease, but without proof of efficacy 3,6,9,11,12.  In a few patients, IVIg have 
been used, in association with cyclosporine6 plasmapheresis 13,14 or rituximab
15, as second line 
treatment in patient with liver disease, however with conflicting efficacy, usually limited to a slight 
reduction of aminotransferase activity. Repeated IVIg infusions at immunomodulatory doses 
induced remission of the liver disease and allowed corticosteroid discontinuation in two infants 
with GCH-AHA with severe steroid-related side effects 16,17. 
The aim of this prospective, uncontrolled, multicenter study, was to evaluate the efficacy and 
safety of IVIg treatment in inducing and maintaining remission of the liver disease, in infants with 
GCH-AHA, as first line therapy and as a steroid-sparing treatment.  
 
Patients and methods 
Seven patients diagnosed with GCH-AHA, in 5 pediatric gastroenterology and hepatology units in 
Italy were included in the study. The local ethical committee approved the study. Parents were 
informed and signed a formal consent. Patients’ characteristics at diagnosis are summarized in the 
table. All patients had clinical and biochemical signs of liver disease with diffuse giant cell 
transformation on liver biopsy and a Coombs-positive (IgG+C type) hemolytic anemia. Liver-
disease related autoantibodies were absent in all. All other known causes of toxic, viral or 
metabolic liver disease were excluded. Five of the seven children were girls and median age at the 
beginning of the study was 2,1 years (range 7 months- 6,2 years).  In six patients the onset of AHA 
preceded that of the liver disease by less than a month, and in a patient by 6 months.  
Three of the six patients were jaundiced at presentation and two infant girls developed a severe 
interstitial pneumonia requiring intensive care. 
Four patients were newly diagnosed, while three had previously been treated by prednisone, 
azathioprine and/or cyclosporine from 8 months, 2 and 5 years respectively, before entering in the 
study. One of these three patients had experienced multiple relapses and had been previously 
treated also with tacrolimus, rapamicin and rituximab. All patients had an elevation of 
aminotransferase activities and one patient had a severe reduction of prothrombin activity. 
All patients received, as first line therapy, an IVIg infusion (0.5 to 2 g/Kg): four patients at the time 
of diagnosis and three during a relapse, while treated with different immunosuppressive drugs 
(prednisone and azathioprine in all, cyclosporine in two and tacrolimus in one). 
In a second phase of the study, five of the seven patients received sequential IVIg infusions with a 
mean of 17 doses (range 7 to 24 doses) administered once a month. All patients were 
contemporary treated with an immunosuppressive therapy (prednisone in all, associated with 
azathioprine in four, cyclosporine in two and tacrolimus in one). The two patients who did not 
progressed to the second part of the study were treated with prednisone and azathioprine, 
associated with cyclosporine in a case. 
Serum aminotransferase and gamma glutamyl-transpeptidase activities, serum albumin and 
gamma globulins levels, serum immunoglobulins, prothrombin time, blood cell and reticulocyte 








Administration of a single immunosuppressive dose of IVIg, as a first line therapy, reduced 
significantly, in all patients, alanine aminotransferase (ALT) activity from a median value of 22,6 x 
upper limit of normal (N) to 5,6 x N (p=0,03) (figure). Moreover, prothrombin activity, in the single 
patient in which it was severe reduced (36%), normalized.   
Concerning the 5 patients who received sequential infusions of IVIg:  three normalized ALT activity 
in a median time of 4 months (range 3- 5 months) and prednisone could be tapered in all of them. 
In two other patients, ALT activity significantly decreased, however remaining within 2 times the 
upper normal limit of normal. In these two patients, immunosuppressive therapy was maintained 
at the same dosage and in one of them rituximab was associated to therapy.  
At the end of follow up (median 17.4 months, range 7-24 months): two of the five patients were 
still in complete disease remission, after a median time of 23 months from the beginning of IVIg 
treatment. In these two patients, prednisone could be tapered maintaining the remission of the 
liver disease. However, in both, hemolytic anemia relapsed. The three other patients relapsed of 
their liver disease after a median of 7.3 months from the beginning of sequential IVIg infusions on 
tapering of prednisone.  
All children have tolerated IVIg infusions with mild side effects in two patients: urticaria in one and 




GCH-AHA is a severe disease of infancy targeting hepatocytes and red blood cells and causing 
severe anemia and diffuse liver injury often progressing to end stage liver failure. Since its first 
description, high doses of prednisone have been shown to avoid the progression of the disease, 
but discontinuation of therapy has been always associated with severe relapse or death1. For this 
reason, patients with GCH-AHA have been treated with a more aggressive immunosuppressive 
therapy always including prednisone.  This multiple immunosuppressive therapy carries a high risk 
of developing severe bacterial infections that, together with terminal liver failure, are the main 
causes of death in such children2. The resistance to immunosuppressive therapy, unusual for 
autoimmune liver diseases of infancy and childhood, that is responsible for the high mortality and 
high rate of recurrence of GCH-AHA, might be explained by peculiar autoimmune mechanisms of 
the disease, based on the humoral immunity instead of “classical” T cell autoimmune response8.  
For these reasons, the therapeutic approach of infants with GCH-AHA, up to now empirically 
based on the experience of few centers on a small number of patients, is today under 
reconsideration. Rituximab (RTX), which is believed, in particular, to deplete CD20-positive auto-
reactive plasma cells sparing protective antimicrobial plasma cells18, was recently shown to induce 
and maintain remission in small series of patients with severe liver disease9,10. Moreover, RTX has 
been also shown to act as steroid-sparing drug, allowing the weaning from corticosteroids 
therapy, particularly in case of an early treatment 10. However, because of a lack of immediate 
effect of this drug, attributed to the autoantibodies half-life, with persisting deleterious effects on 
the liver cells, RTX was suggested to be always associated with a short acting drug, such as 
corticosteroids10.  In fact, the almost constant severe and aggressive onset of the disease, induce 
to obtain a rapid reduction of the activity of the disease to ameliorate liver function. Moreover, 
liver transplantation is not a safe therapeutic option in GCH-AHA, because of the high risk of 
recurrence in the graft 4.  
This study first demonstrate in a small series of patients with GCH-AHA, that IVIg associated with 
prednisone, when used as first line therapy, significantly and rapidly reduce the activity of the liver 
disease, as shown by the decrease of aminotransferase activity in serum and by normalization of 
prothombin activity in the patient with severe liver dysfunction. Moreover, sequential infusions of 
IVIg at monthly intervals, were associated with a steroid sparing effect and allow to obtain 
complete or partial remission in all patients, confirming previous reports in single cases16,17 . 
However the efficacy of periodical infusion of IVIG was temporary and relapse of the hemolytic 
anemia and/or of the liver disease occurred in all patients. 
 IVIg acts at different levels of the immune response, neutralizing auto-antigens, inhibiting the 
activation and proliferation of T and B cells, saturating the Fc receptors of the immune globulins 
and modulating cytokine network 19-20. Furthermore, IVIg are able to inhibit complement mediated 
tissue damage by preventing the generation of C5b-9 membrane attack, scavenging active 
complement components and diverting complement attack from cellular targets 19,20. Moreover, 
IVIg have a few mild adverse effects comparing to steroids, all resolve by stopping the infusion and 
may be prevented by anti inflammatory drugs infusion before IVIg 20. 
The main limit of our study is related to the limited number of patients, but the rarity of the 
disease strongly limits the feasibility of a study on a larger number of patients. 
We thus propose that, in patients with GCH-AHA, infusion, at immunomodulatory dose, of IVIG 
should be performed, at diagnosis, in association with prednisone and azathioprine to improve the 
immunosuppressive effect of these drugs, particularly in case of marked increase of 
aminotransferase activity and liver cell function impairment. IVIg may be also used in case of 
relapse of the liver disease occurring during the attempt of discontinuation of the steroid 
treatment. 
Although repeated IVIg infusion therapy allows, in our study, to obtain a complete or partial 
remission of liver disease and to reduce the dose of corticosteroids, we believe that, due to its 
only temporary efficacy , should not be employed.   
Due to the recent results concerning the efficacy and safety of RTX use in patients with the more 
severe forms of GCH-AHA we believe that RTX treatment should be the second line treatment in 
patients with early relapse at discontinuation of steroid treatment. RTX should however be 
handled with caution due to the potential side effects and in particular of persistent  




Figure: Aminotransferase activity before and a month after the infusion of IVIG at 


















Table: Characteristic of the 7 patients with GCH-AHA at diagnosis. 
 







Patients n° 1 n° 2  n°3  n° 4 n°5 n° 6  n° 7  
Sex F M F F F F M 
Age at onset of 
AHA  
(months) 
5 8 10 10 6 7 8 








Jaundice - + - + + - - 
Pallor + + + + + - + 
Hepatomegaly + - + + - - + 
Splenomegaly - - + +  - - 
Hemoglobin  
(g/dl) 
9,8 10,7 9,8 6,3 8,5 11  8,7 
ALT (x ULN) 160 16 19 90 39 20 28,9 
GGT (x ULN) 4 1,5 2,8 2.8 2,8 N 3,9 
Total Bilirubin 
mg/dl 
1,5 3,9 1,5 4.5 5 0,5 1,96 
Prothrombin 
activity  % 
78 93 43 49 100 100 68 
Liver histology  
Giant cell 
transformation 
+++ +++ +++ +++ +++ +++ +++ 
Portal and 
periportal      
inflammation 
+ ++ ++ ++ ++ + + 






















      Portal 
fibrosis 
+ + ++ ++ + + + 
References 
  
1. Bernard O, Hadchouel M, Scotto J, Odievre M, Alagille D. Severe giant cell hepatitis with 
autoimmune hemolytic anemia in early childhood. J Pediatr 1981; 99: 704-11 
 
2. Maggiore G, Sciveres M, Fabre M, et al. Giant cell hepatitis with autoimmune hemolytic 
anemia in early childhood: long-term outcome in 16 children. J Pediatr 2011; 159:127-32  
 
3. Hadzic N, Portmann B, Lewis I, Mieli-Vergani G. Coombs positive giant cell hepatitis--a new 
feature of Evans' syndrome. Arch Dis Child 1998; 78: 397-8. 
 
4. Melendez HV, Rela M, Baker AJ, Ball C, Portmann B, Mieli-Vergani G, Heaton ND. Liver 
transplant for giant cell hepatitis with autoimmune haemolytic anaemia. Arch Dis Child 
1997; 77: 249-51. 
 
5. Gorelik M, Debski R, Frangoul H. Autoimmune hemolytic anemia with giant cell hepatitis: 
case report and review of the literature. J Pediatr Hematol Oncol 2004; 26: 837-9. 
 
6. Vajro P, Migliaro F, Ruggeri C, et al. Life saving cyclophosphamide treatment in a girl with 
giant cell hepatitis and autoimmune haemolytic anaemia: case report and up-to-date on 
therapeutical options. Dig Liver Dis 2006; 38: 846-50. 
 
7. Longhi MS, Ma Y, Mieli-Vergani G, Vergani D. Aetiopathogenesis of autoimmune hepatitis. J 
Autoimmun 2010; 34:7-14 
 
8. Whitington PF, Vos MB, Bass LM, Melin-Aldana H, Romero R, Roy CC, Alvarez F. Humoral 
immune mechanism of liver injury in giant cell hepatitis with autoimmune hemolytic 
anemia. J Pediatr Gastroenterol Nutr. 2014; 58: 74-80 
 
9. Bakula A, Socha P, Klaudel-Dreszler M, Karolczyk G, Wozniac M, Rutynowska O, Matysiak 
M. Giant cell hepatitis with autoimmune hemolytic anemia in children: proposal for 
therapeutic approach. J Pediatr Gastroenterol Nutr 2014; 58: 669-73 
 
10. Paganelli M, Patey N, Bass LM, Alvarez F. Anti-CD20 treatment for giant cell hepatitis with 
autoimmune hemolytic anemia. Pediatrics 2014; in press 
 
11. Kashyap R, Sarangi JN, Choudhry VP. Autoimmune hemolytic anemia in an infant with giant 
cell hepatitis. Am J Hematol 2006; 81:199-201. 
 
12. Perez-Atayde AR, Sirlin SM, Jonas M. Coombs-positive autoimmune hemolytic anemia and 
postinfantile giant cell hepatitis in children. Pediatr Pathol 1994; 14: 69-77. 
 
13. Hartman C, Berkowitz D, Brik R, Arad A, Elhasid R, Shamir R. Giant cell hepatitis with 
autoimmune hemolytic anemia and hemophagocytosis. J Pediatr Gastroenterol Nutr 2001; 
32: 330-4 
 
14. Imgrueth M, Wagner HP, Pipczynski-Suter K, et al. Plasma exchange: an important part of 
the therapeutic procedure in a small child with autoimmune hemolytic anemia. Acta 
Paediatr Scand 1986;75: 1037-41 
 
15. Miloh T, Manwani D, Morotti R, Sukru E, Shneider B, Kerkar N. Giant cell hepatitis and 
autoimmune hemolytic anemia successfully treated with rituximab. J Pediatr Gastroenterol 
Nutr 2007; 44: 634-6 
 
16. Lachaux A, Bertrabd Y, Bouvier R, Dumant C, Pinzaru M, Hermier. Intravenous 
immunoglobulin therapy in an infant with autoimmune hemolytic anemia associated with 
necrotic hepatitis and peliosis. J Pediatr Gastroenterol Nutr 1996; 22: 99-102 
 
17. Lega S, Maschio M, Taddio A, Maggiore G, Ventura A. Giant cell hepatitis with Coombs-
positive haemolytic anaemia: steroid sparing with high-dose intravenous immunoglobulin 
and cyclosporine. Acta Paediatr. 2013; 102: 137-9 
 
18. Huang H, Benoist C, Mahtis D. Rituximab specifically depletes short-lived autoreactive 
plasma cells in a mouse model of inflammatory arthritis. Proc Natl Acad Sci USA 2010; 107: 
4658-4663 
 
19. Siberil S, Elluru S, Negi VS, et al. Intravenous immunoglobulin in autoimmune and 
inflammatory diseases: more than mere transfer of antibodies. Transfus Apher Sci 2007; 
37: 103-7 
 
20. Negi VS, Elluru S, Siberil S, et al. Intravenous immunoglobulin: an update on the clinical use 
and mechanism of action. J Clin Immunol 2007; 27: 233-45 
 
 
